nach oben

Erschienen in:

20.07.2022 | Review Article

Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study

verfasst von: Yawen Wang, Jiadai Xu, Jing Li, Zheng Wei, Miaojie Shi, Rong Tao, Bobin Chen, Yuyang Tian, Wenhao Zhang, Yan Ma, Lihua Sun, Yunhua Hou, Qilin Zhan, Jigang Wang, Hongwei Xue, Peng Liu

Erschienen in: Annals of Hematology | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Marginal zone lymphoma (MZL) is an uncommon subtype of non-Hodgkin lymphoma (NHL). Combination of rituximab and cladribine (R-2CdA) is a potential option for indolent NHL (iNHL) and mantle cell lymphoma (MCL) patients. The goal of this multicenter retrospective study was to assess the efficacy and safety of R-2CdA in MZL to support consensus-reaching in first-line therapy in advanced-stage patients. We searched electronic medical records databases of eight centers in China. Between November 2014 and December 2019, 183 symptomatic advanced MZL patients (42 treated with R-2CdA and 141 with rituximab plus cyclophosphamide, adriamycin, vincristine, and prednisone [R-CHOP]) were identified. After propensity score matching (PSM) (1:1) to adjust for clinical characteristics, 39 patients from each treatment arm were selected. The overall response rate (ORR) (84.6% vs. 94.9%, P = 0.263) and complete response rate (59.0% vs. 66.7%, P = 0.487) were comparable between two protocols. Neither progression-free survival (PFS), including the 5-year PFS (67.7% vs. 56.1%, P = 0.352), nor overall survival was improved by R-2CdA versus R-CHOP. However, R-2CdA was more tolerable than R-CHOP in MZL patients regarding grade 3/4 hematological adverse events (odds ratio [OR] 0.565, 95% confidence interval [CI] neutropenic fever (OR 0.795, 95% CI 0.678–0.932), and infections (OR 0.800, 95% CI 0.640–1.000). Overall, our study demonstrated that R-2CdA is potentially as effective as but safer than R-CHOP in advanced MZL.

Nur mit Berechtigung zugänglich

Olszewski AJ, Castillo JJ (2013) Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 119(3):629–638CrossRef

(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89(11):3909–3918

Xiao-qiu L, Gan-di L, Zi-fen G, Xiao-ge Z, Xiong-zeng Z (2012) Group tCLS: Distribution of lymphoma subtypes in China: analysis of 10002 multicentric cases in China. J Diagn Concepts Pract 11(2):5

Sindel A, Al-Juhaishi T, Yazbeck V (2019) Marginal zone lymphoma: state-of-the-art treatment. Curr Treat Options Oncol 20(12):90CrossRef

Sriskandarajah P, Dearden CE (2017) Epidemiology and environmental aspects of marginal zone lymphomas. Best Pract Res Clin Haematol 30(1–2):84–91CrossRef

Perrone S, D’Elia GM, Annechini G, Pulsoni A (2016) Infectious aetiology of marginal zone lymphoma and role of anti-infective therapy. Mediterr J Hematol Infect Dis 8(1):e2016006CrossRef

Raderer M, Kiesewetter B, Ferreri AJ (2016) Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin 66(2):153–171CrossRef

Iannitto E, Tripodo C (2011) How I diagnose and treat splenic lymphomas. Blood 117(9):2585–2595CrossRef

Zucca E, Bertoni F (2016) The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood 127(17):2082–2092CrossRef

10.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C et al (2017) Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol 35(17):1905–1912CrossRef

11.

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210CrossRef

12.

Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J et al (2019) First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37(12):984–991CrossRef

13.

Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92(6):1918–1926CrossRef

14.

Delannoy A (1996) 2-chloro-2′-deoxyadenosine: clinical applications in hematology. Blood Rev 10(3):148–166CrossRef

15.

Sigal DS, Saven A (2008) Cladribine in indolent non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther 8(4):535–545CrossRef

16.

Wei Z, Li J, Cheng Z, Yuan L, Liu P (2017) A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma. J Thorac Dis 9(4):1081–1092CrossRef

17.

Jäger G, Neumeister P, Quehenberger F, Wöhrer S, Linkesch W, Raderer M (2006) Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 17(11):1722–1723CrossRef

18.

Kiesewetter B, Dolak W, Simonitsch-Klupp I, Mayerhoefer ME, Raderer M (2017) Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. Hematol Oncol 35(2):177–186CrossRef

19.

Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51CrossRef

20.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRef

21.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586CrossRef

22.

Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, Delmer A, Salles G, Morschhauser F, Delarue R et al (2012) Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica 97(10):1594–1602CrossRef

23.

Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR et al (2019) Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874–882CrossRef

24.

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S et al (2017) Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 129(16):2224–2232CrossRef

25.

Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJM, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F et al (2011) Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 22(3):689–695CrossRef

26.

Jäger G, Höfler G, Linkesch W, Neumeister P (2004) Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica 89(4):Ecr01PubMed

27.

Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC (1997) Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia 11(1):170CrossRef

28.

Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y et al (2020) Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 4(15):3699–3707CrossRef

Titel: Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study
verfasst von: Yawen Wang
Jiadai Xu
Jing Li
Zheng Wei
Miaojie Shi
Rong Tao
Bobin Chen
Yuyang Tian
Wenhao Zhang
Yan Ma
Lihua Sun
Yunhua Hou
Qilin Zhan
Jigang Wang
Hongwei Xue
Peng Liu
Publikationsdatum: 20.07.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 10/2022
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-022-04919-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura

Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review

Clinical characteristics and treatment of NK/T-cell lymphoma–associated HLH

Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia

Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory

Can we restart the rituximab after remission of rituximab-induced interstitial lung disease in malignant lymphoma?